Channing J Paller

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Management of bone metastases in refractory prostate cancer--role of denosumab
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Clin Interv Aging 7:363-72. 2012
  2. doi request reprint Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Hum Vaccin Immunother 8:509-19. 2012
  3. pmc Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 11:14-23. 2013
  4. pmc Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011

Detail Information

Publications4

  1. pmc Management of bone metastases in refractory prostate cancer--role of denosumab
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Clin Interv Aging 7:363-72. 2012
    ..The role of denosumab in prostate cancer will continue to evolve either as monotherapy or in combination with other bone-targeting strategies...
  2. doi request reprint Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Hum Vaccin Immunother 8:509-19. 2012
    ....
  3. pmc Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 11:14-23. 2013
    ..This review will summarize the acceptable standards of care for the management of biochemically recurrent prostate cancer, and will also outline some novel experimental approaches for the treatment of this disease state...
  4. pmc Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Channing J Paller
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
    Drug Des Devel Ther 5:117-24. 2011
    ....